Breaking News

Financial Report: Biogen Idec

April 23, 2014

51% growth driven by MS franchise

Biogen Idec
 
1Q Revenues:
$2.1 billion (+51%)

1Q Earnings: $480 million (+12%)

Comments: TECFIDERA, recently approved for MS patients in Europe, had revenues of $506 million, comprised of $460 million the U.S. and approximately $46 million outside the U.S. AVONEX revenues increased 2% to $761 million. TYSABRI revenues were up 41% to $441 million due to recording 100% its revenues following the acquisition of complete asset rights in 2Q13. RITUXAN and GAZYVA revenues from an unconsolidated joint business arrangement were $297 million.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision